Ventures News

05/29/2018

ClearFlow Announces Additional Positive US Clinical Trial Results at the 2018 NTI Critical Care Exposition

ClearFlow, Inc., a medical device company based in Anaheim, California, has announced that positive clinical trial results were presented at the National Teaching Institute (NTI) & Critical Care Exposition 2018 annual meeting on May 23rd, 2018 in Boston, MA. The findings were presented by the study principal investigator, Dr. Yvon Baribeau, of Catholic Medical Center in Manchester, New Hampshire, in a presentation titled “Active Clearance of Chest Drains Reduces Pleural Effusions and ICU Resources in patients undergoing Cardiac Surgery.”


05/29/2018

Cleveland Clinic spinoff is at the center of efforts to remake the operating room

Centerline Biomedical, a Cleveland Clinic spinoff, is part of this Wall Street Journal story about tech advances that are making the operating room "smarter, more effective — and a lot less risky for patients."


05/29/2018

Merchavia Reports Positive Results in a Breakthrough Trial for Early Prostate Cancer Diagnosis

Merchavia Holdings and Investments (TASE: MRHL), an Israeli investment company specializing in early-stage life science sector companies, reports positive results from a successful trial which was conducted Cleveland Clinic, a leading medical center, using IsoPSA, a test developed by CDx (in which Merchavia holds about 8%).


05/21/2018

NaviGate Cardiac Structures Inc. (“NCSI”) reports “excellent valvular function” at 1-year follow-up of first patient to receive GATE™ tricuspid valved stent via transjugular access

NaviGate Cardiac Structures Inc. (“NCSI”) announced today that the first patient to receive its replacement tricuspid valved stent via transjugular access has reached one-year post-procedure with excellent valvular function.


05/19/2018

Assay May Help Avoid Needless Prostate Biopsies

An assay that identifies abnormal PSA proteins showed promise as an aid to avoid unnecessary prostate biopsies triggered by worrisome PSA test results, according to data reported here.


05/01/2018

ClearFlow Reports: ERAS Cardiac Surgery Recommends Active Tube Clearance Methodology in Consensus Statement Presented at the 98th Annual Meeting of The American Association for Thoracic Surgeons

ClearFlow Inc. has announced that an international society of leading heart surgeons known as ERAS® Cardiac Surgery presented evidenced-based expert consensus statements at the 98th annual meeting of the American Association for Thoracic Surgeons on April 28, 2018.


03/12/2018

Pulsante® Therapy Awarded Prestigious Forfait Innovation Package to Fast-Track Medical Innovation for Cluster Headache in France

Autonomic Technologies, Inc., today announced that the College of the French National Authority for Health (HAS) issued a favorable opinion on a Forfait Innovation package for the Pulsante® SPG Microstimulator System. The award will support a randomized controlled trial for patients suffering from cluster headache.


03/01/2018

This Smart Mouthguard Can Monitor Concussions

If you watched the Super Bowl LII earlier this month, you'll recall a moment in the second quarter when Patriots quarterback Tom Brady found Brandin Cooks wide open for a beautiful, 23-yard completion. But when Cooks turned to run for the end zone, he didn’t see Eagles safety Malcolm Jenkins gunning for him on the left. Like Jaws, Jenkins roared out of the murky deep, and leveled Cooks with a vicious hit to the head.


01/09/2018

Prevent Biometrics® Announces Commercial Launch of Head Impact Monitor System, Bringing Advanced Real-Time Monitoring of Concussion Impacts to Sports

Prevent Biometrics, the Cleveland Clinic spinoff that created the first and only head impact monitoring technology to accurately detect potential concussion-causing impacts in real time, announces its newest innovation at the Consumer Electronics Show today: the Gen 1.2 Head Impact Monitor System, bringing advanced, never-before-available head impact analytic capabilities to schools, associations, teams and coaches. 


01/04/2018

Centerline Biomedical Completes Fifth Preclinical Study

As Centerline Biomedical, Inc. prepares to meet with investors, strategic partners and companies in the healthcare industry during the JP Morgan Healthcare Conference, it successfully completed a fifth preclinical study at Cleveland Clinic facilities evaluating its surgical navigation system, IOPS, the Intra-Operative Positioning System. This study was the most noteworthy Centerline study to date, demonstrating ability to track sensorized IOPS instruments precisely and efficiently, with enhanced 3-D visualization, without frequent exposure to cancer-causing ionizing radiation associated with current standard of care. Endovascular surgeries i.e. those which repair arteries using stents rely on X-ray fluoroscopy, which provides limited two-dimensional visualization, leading to long procedure times while exposing surgeons and patients to damaging radiation. IOPS, originally developed at Cleveland Clinic, uses a 3-D model of a patient's vascular system to track instruments precisely without ionizing radiation, with the goal of reducing procedure times, complication rates, and overall costs. The mathematical algorithms used to generate the 3-D model are currently being used to revolutionize minimally invasive surgery, with future applications in surgical training and clinical decision support.


   <  1 - 2 - 3 - 4  >   

Get In Touch With Us